<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
Sheri Crockett,<p>
Genex Pharmaceutical, Inc. (OTCBB: GENX)<P>
Chinese Biotech Company Producing Reconstituted Bone Xenograft (RBX)
Signs Letter of Intent to Acquire Vitamin B1 Manufacturer that
Posted US $16 MILLI0N in Revenue for Fiscal 2003 and Net Income of
Approximately US $3 MILLI0N<P>
The 10Q which was released on August 16th showed revenues of
$525,750 for the quarter ending June 30th. vs. $98,763 for the same
period a year ago. Net Income three months ended June 30, 2004:
$151,904 vs. a loss of $3,929 for the same period a year ago.<P><P>
About Genex Pharmaceutical, Inc.<P>
Product Distributed to 400 Hospitals in 22 Provinces<P>
Genex Pharmaceutical, Inc. is a biomedical technology company with
distinctive proprietary technology for an orthopedic device that
treats bone-related injuries. Headquartered in Tianjin, China, the
Company manufactures and distributes Reconstituted Bone Xenograft
(RBX), to 400 hospitals in 22 provinces throughout mainland China.
RBX is approved by the State Food and Drug Administration (SFDA) in
China (the Chinese government agency that regulates drugs and
medical devices). RBX offers a modern alternative to traditional
methods of treating orthopedic injuries. (Source: News Release
7/27/04)<P><P>
Recent Press Release Headlines:<P>
The Good News Keeps on Coming for GENX - Go Read the Full Stories!<P>
*Genex Pharmaceutical Adopts New Proprietary Technology,
Substantially Reduces Manufacturing Costs, Sees Positive Impact to
Earnings.<P>
*Genex Pharmaceutical Signs Letter of Intent to Acquire One of the
World's Largest Producers of Vitamin B1.<P>
*Genex Pharmaceutical Sees Strong Earnings Growth for 2004 and 2005.<P>
*Genex Pharmaceutical 2nd Quarter Revenue Up 432%, Gross PR0FIT Up
380%, Net INC0ME Soars, Sees Continued Earnings Momentum for
Remainder of 2004.<P><P>
Strongly Consider The Following:<P>
Many investors (some of them are now called milli0naires), see the
potential for emerging companies before the numbers grab Wall
Street's Attention. That 's how the big money is made! Were they
just lucky? I don't think so- and as an investor, I suspect you
don't either. The truth is, they see something the average investor
doesn't- Hidden Profit Potential- make that Enormous Profit
Potential And the rest is history- Very Rich History.<P>
Read the announcements GENX has made. Look at the Company. Read the
Filings. Do you see the Potential for Explosive Growth? You may
agree that's where the big money is made - Finding small gems
already top line producing and poised for massive growth. Consider
GENX for your portfolio today. Good Luck and Successful Investing.<P><P>
DIS-CLAIMER: Information within this ema-il contains F0RWARD looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not
statements of historical fact and may be forward looking statements.
Forward looking statements are based on expectations, estimates and
projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results
or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through
the use of words such as projects , foresee, expects, will,
anticipates, estimates, believes, understands or that by statements
indicating certain actions may, could, or might occur. As with many
micro-cap stocks, today's company has additional risk factors worth
noting. Those factors include: a limited operating history: the
company advancing cash to related parties and a shareholder on an
unsecured basis: one vendor, a related party through a majority
stockholder, supplies ninety-seven percent of the company's raw
materials: reliance on two customers for over fifty percent of their
business and numerous related party transactions and the need to
raise capital.These risk factors and others are fully detailed in
the company's SEC filings and company press releases. We urge you to
read them before you invest. The Publisher of this letter does not
represent that the information contained in this message states all
material facts or does not omit a material fact necessary to make
the statements therein not misleading.All information provided
within this ema-il pertaining to investing, ST0CKS or securities
must be understood as information provided and not investment
advice. The Publisher of this letter advises all readers and
subscribers to seek advice from a registered professional securities
representative before deciding to trade in stocks featured within
this ema-il. None of the material within this report shall be
construed as any kind of investment advice or solicitation. Many of
these companies are on the verge of bankruptcy. You can lose all
your money by investing in this stock. The Publisher of this letter
is not a registered investment ADVIS0R. Subscribers should not view
information herein as legal, tax, accounting or investment advice.
Any reference to past performance(s) of companies are specially
selected to be referenced based on the favorable performance of
these companies. You would need perfect timing to acheive the
results in the examples given. There can be no assurance of that
happening.Remember, as always, past performance is ne-ver indicative
of future results and a thorough due diligence effort, including a
review of a company's filings, should be completed prior to
investing. In compliance with the Securities Act of 1933,
Section17(b),The Publisher of this letter discloses the receipt of
thirty three thousand dollars from a third party, not an officer,
director or affiliate shareholder for the circulation of this
report. Be aware of an inherent conflict of interest resulting from
such compensation due to the fact that this is a paid adver-tisement
and is not without bias. All factual information in this report was
gathered from public sources, including but not limited to Company
Websites, SEC Filings and Company Press Releases. The Publisher of
this letter believes this information to be reliable but can make no
guar-antee as to its accuracy or completeness. Use of the material
within this ema-il constitutes your acceptance of these terms.
aural ,intestine .<p>
%RND_SYB<p>
,chelate ,suzerainty .<p>